NHS
North East and Yorkshire
Genomic Laboratory Hub

Genetic Testing Request Form
Rare Disease

Lab Use Only

Lab No:
Date received:

Patient Information – use sticker if available				**Requesting Consultant / Genetic Counsellor**	
NHS No:		**D.O.B:**		**Full Name**	
Surname:		**Sex:**		**Contact E-mail:**	
Forename:		**Ethnicity:**		**Hospital:**	
Patient's Address: **Postcode:**		**Hospital No:**		**Ward /Clinic:**	
		Clinical Genetics No:		**Address/Email for report:**	

R208	☐	Test: Inherited breast cancer and ovarian cancer
R444	☐	**Test:** NICE approved PARP inhibitor treatment

Please tick if **urgent** ☐

		TICK
PLEASE SPECIFY REASON FOR URGENCY	**R208:** undergone/underwent breast conservation, only adjuvant radiotherapy planned	☐
	R444.1: no planned adjuvant chemotherapy, consider PARP	☐

Other relevant details:

Extracted DNA will be stored in the laboratory, please tick box if consent for storage has NOT been given ☐

	R208	**Living affected individual (proband) with breast cancer (including high grade DCIS) where the individual meets one of the criteria. The proband has:**
☐		Breast cancer (age < 40 years)
☐		Bilateral breast cancer (age < 60 years)
☐		Triple negative breast cancer (age < 60 years)
☐		Assigned male at birth and affected with breast cancer (any age)
☐		Ashkenazi Jewish ancestry and breast cancer at any age
☐		≥ 1 grandparent from Westray (Orkney) or Whalsay (Shetland) and breast cancer at any age
	PLEASE NOTE: Other Test Directory criteria rely on family history confirmation – please discuss these cases with, or refer these patients to, Clinical Genetics	
	R444	**Applies only applies to patients not meeting R208 criteria AND with current cancer diagnosis, for treatment decisions.**
☐		For people with triple negative breast cancer who have received neo-adjuvant chemotherapy: residual invasive cancer in the breast, the resected lymph nodes (non-pathological complete response) or both at the time of surgery
☐		For people with triple-negative breast cancer having adjuvant chemotherapy: (node-positive OR node-negative cancer with a primary tumour ≥ 2 cm)
☐		For people with hormone receptor-positive, HER2-negative breast cancer who have received neoadjuvant chemotherapy **WITH** residual invasive cancer in the breast **OR** the resected lymph nodes (non-pathologic complete response) **OR** both at the time of surgery, **AND** a CPS + EG score of ≥3 based on pre-treatment clinical and post-treatment pathological stage, receptor status and histological grade
☐		For people with hormone receptor-positive, HER2-negative breast cancer having adjuvant chemotherapy: (4 or more pathologically confirmed positive lymph nodes)
☐		For people who have HER2-negative locally advanced or metastatic breast cancer: Patients should have been previously treated with an anthracycline and/or a taxane in the neo/adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments **OR** Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine-based therapy, or be considered unsuitable for endocrine-based therapy

Specimen details	**Sample Date:**		**Sample Type:**	EDTA Blood (2 - 5ml)	**Taken by:**	

NHS
North East and Yorkshire
Genomic Laboratory Hub

Once taken, samples should be sent to your local Genetics Laboratory

Please ensure a minimum of 3 matching identifiers on tubes and form
Samples packed according to UN3373 / P1650 and sent 1st class post will normally be suitable for DNA extraction.
Please store samples at 4°C if they cannot be transported the same day.

Newcastle Genetics Laboratory

Newcastle Genetics Laboratory
Central Parkway
Newcastle upon Tyne
Tyne and Wear
NE1 3BZ

NUTH.DNA@nhs.net

0191 241 8787/8775/8754

www.newcastlelaboratories.com/lab_service/laboratory-rare-diseases-services/